{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:17Z","timestamp":1772119997156,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Henan Provincial Key Technology Research and Development Program","award":["No.162102310305"],"award-info":[{"award-number":["No.162102310305"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03062-z","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:02:58Z","timestamp":1759554178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1\/2-Bim and AKT1\/Noxa signals in pancreatic cancer cells"],"prefix":"10.1007","volume":"42","author":[{"given":"Bing","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfeng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"3062_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"3062_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1615\/CritRevOncog.2019031641","volume":"24","author":"D Sarvepalli","year":"2019","unstructured":"Sarvepalli D, Rashid MU, Rahman AU, Ullah W, Hussain I, Hasan B, et al. Gemcitabinecitabine: a review of chemoresistance in pancreatic cancer. Crit Rev Oncog. 2019;24:199\u2013212.","journal-title":"Crit Rev Oncog"},{"key":"3062_CR3","doi-asserted-by":"publisher","first-page":"920","DOI":"10.2174\/1389557517666170315124438","volume":"17","author":"B Marasini","year":"2017","unstructured":"Marasini B, Sahu RP. Natural anti-cancer agents: implications in Gemcitabine-resistant pancreatic cancer treatment. Mini Rev Med Chem. 2017;17:920\u20137.","journal-title":"Mini Rev Med Chem"},{"key":"3062_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2020.03.008","volume":"181","author":"M Ruscetti","year":"2020","unstructured":"Ruscetti M, Morris JP 4th, Mezzadra R, Russell J, Leibold J, Romesser PB, et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell. 2020;181:424-441.e21.","journal-title":"Cell"},{"key":"3062_CR5","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, Mick R, O\u2019Hara MH. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39:2497\u2013505.","journal-title":"J Clin Oncol"},{"key":"3062_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e15753","volume":"34","author":"JM Eatrides","year":"2016","unstructured":"Eatrides JM, Coppola D, Al Diffalha S, Kim RD, Springett GM, Mahipal A. Microsatellite instability in pancreatic cancer. J Clin Oncol. 2016;34:e15753.","journal-title":"J Clin Oncol"},{"key":"3062_CR7","doi-asserted-by":"crossref","unstructured":"Sotorasib tackles KRASG12C-mutated pancreatic cancer. Cancer Discov. 2022;12:878\u2013879.","DOI":"10.1158\/2159-8290.CD-NB2022-0015"},{"key":"3062_CR8","doi-asserted-by":"crossref","unstructured":"Ardalan B, Ciner A, Baca Y, Hinton A, Darabi S, Kasi A, Lou E, Azqueta JI, Xiu J, Datta J, Shields AF, Aguirre A, Singh H, Shroff RT, Pishvaian MJ, Goel S. Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma. Clin Cancer Res. 2025.","DOI":"10.1158\/1078-0432.c.7722384"},{"issue":"12","key":"3062_CR9","first-page":"274","volume":"27","author":"F Liu","year":"2024","unstructured":"Liu F, Gao A, Zhang M, Li Y, Zhang F, Herman JG, et al. Methylation of FAM110C is a synthetic lethal marker for ATR\/CHK1 inhibitors in pancreatic cancer. J Transl Int Med. 2024;27(12):274\u201387.","journal-title":"J Transl Int Med"},{"key":"3062_CR10","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, Mick R, O\u2019Hara MH, Teitelbaum U, Karasic TB, Schneider C, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39:2497\u2013505.","journal-title":"J Clin Oncol"},{"key":"3062_CR11","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-23-2893","volume":"30","author":"A Voisin","year":"2024","unstructured":"Voisin A, Terret C, Schiffler C, Bidaux AS, Vanacker H, Perrin-Niquet M, et al. Xevinapant combined with pembrolizumab in patients with advanced, pretreated, colorectal and pancreatic cancer: results of the phase Ib\/II CATRIPCA trial. Clin Cancer Res. 2024;30:2111\u201320.","journal-title":"Clin Cancer Res"},{"key":"3062_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Groupe Tumeurs Digestives of Unicancer. FOLFIRINOX versus gemcitabinecitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"3062_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"3062_CR14","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Coldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960\u20136.","journal-title":"J Clin Oncol"},{"key":"3062_CR15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jss.2012.05.065","volume":"178","author":"S Kagawa","year":"2012","unstructured":"Kagawa S, Takano S, Yoshitomi H, Kimura F, Satoh M, Shimizu H, et al. Akt\/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res. 2012;178:758\u201367.","journal-title":"J Surg Res"},{"key":"3062_CR16","first-page":"3747","volume":"31","author":"RA Fryer","year":"2011","unstructured":"Fryer RA, Barlett B, Galustian C, Dalgleish AG. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide. Anticancer Res. 2011;31:3747\u201356.","journal-title":"Anticancer Res"},{"key":"3062_CR17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/0300060512474128","volume":"41","author":"C Zheng","year":"2013","unstructured":"Zheng C, Jiao X, Jiang Y, Sun S. ERK1\/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. J Int Med Res. 2013;41:300\u2013617.","journal-title":"J Int Med Res"},{"key":"3062_CR18","doi-asserted-by":"crossref","unstructured":"Jiang Y, Sohal DPS. Pancreatic adenocarcinoma managemcitabineent. JCO Oncol Pract. 2023;19:19\u201332.","DOI":"10.1200\/OP.22.00328"},{"key":"3062_CR19","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/0008-5472.CAN-12-1453","volume":"73","author":"K Miyabayashi","year":"2013","unstructured":"Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res. 2013;73:2221\u201334.","journal-title":"Cancer Res"},{"key":"3062_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","volume":"3","author":"EJ Morris","year":"2013","unstructured":"Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3:742\u201350.","journal-title":"Cancer Discov"},{"key":"3062_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4161\/cc.5.8.2692","volume":"5","author":"BC van de Weerdt","year":"2006","unstructured":"van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle. 2006;5:853\u201364.","journal-title":"Cell Cycle"},{"key":"3062_CR22","doi-asserted-by":"crossref","unstructured":"Dimri M, Cho JH, Kang M, Dimri GP.PLK1 inhibition down-regulates polycomb group protein BMI1 via modulation of the miR-200c\/141 cluster.J Biol Chem. 2015;290(5):3033\u201344.","DOI":"10.1074\/jbc.M114.615179"},{"key":"3062_CR23","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1074\/jbc.M114.596817","volume":"290","author":"C Shao","year":"2015","unstructured":"Shao C, Ahmad N, Hodges K, Kuang S, Ratliff T, Liu X. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. J Biol Chem. 2015;290:2024\u201333.","journal-title":"J Biol Chem"},{"key":"3062_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/17460441.2024.2385603","volume":"19","author":"M Raab","year":"2024","unstructured":"Raab M, Becker S, Sanhaji M. Targeting polo-like kinase 1: advancements and future directions in anti-cancer drug discovery. Expert Opin Drug Discov. 2024;19:1153\u20137.","journal-title":"Expert Opin Drug Discov"},{"key":"3062_CR25","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/gutjnl-2016-311393","volume":"65","author":"UM Mahajan","year":"2016","unstructured":"Mahajan UM, Teller S, Sendler M, Palankar R, van den Brandt C, Schwaiger T, et al. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer. Gut. 2016;65:1838\u201349.","journal-title":"Gut"},{"key":"3062_CR26","doi-asserted-by":"crossref","unstructured":"Zhang Z, Cheng L, Li J, Qiao Q, Karki A, Allison DB, Shaker N, Li K, Utturkar SM, Atallah Lanman NM, Rao X, Rychahou P, He D, Konieczny SF, Wang C, Shao Q, Evers BM, Liu X. Targeting Plk1 sensitizes pancreatic cancer to immune checkpoint therapy. Cancer Res. 2022(4);82:3532\u201348.","DOI":"10.1158\/0008-5472.CAN-22-0018"},{"key":"3062_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/15384101.2016.1148838","volume":"15","author":"J Li","year":"2016","unstructured":"Li J, Wang R, Schweickert PG, Karki A, Yang Y, Kong Y, et al. Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer. Cell Cycle. 2016;15:711\u20139.","journal-title":"Cell Cycle"},{"key":"3062_CR28","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1158\/0008-5472.CAN-07-5123","volume":"68","author":"S Zhao","year":"2008","unstructured":"Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L, et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res. 2008;68:4221\u20138.","journal-title":"Cancer Res"},{"key":"3062_CR29","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","volume":"22","author":"F Luciano","year":"2003","unstructured":"Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22:6785\u201393.","journal-title":"Oncogene"},{"key":"3062_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jconrel.2015.01.026","volume":"201","author":"C Poon","year":"2015","unstructured":"Poon C, He C, Liu D, Lu K, Lin W. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J Control Release. 2015;201:90\u20139.","journal-title":"J Control Release"},{"key":"3062_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06894-1","volume":"15","author":"M Chiappa","year":"2024","unstructured":"Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D, et al. Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas. Cell Death Dis. 2024;15:521.","journal-title":"Cell Death Dis"},{"key":"3062_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tins.2023.01.003","volume":"46","author":"RM Slominski","year":"2023","unstructured":"Slominski RM, Raman C, Chen JY, Slominski AT. How cancer hijacks the body\u2019s homeostasis through the neuroendocrine system. Trends Neurosci. 2023;46:263\u201375.","journal-title":"Trends Neurosci"},{"key":"3062_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","volume":"7","author":"K Nakano","year":"2001","unstructured":"Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683\u201394.","journal-title":"Mol Cell"},{"key":"3062_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.307","volume":"4","author":"R Hill","year":"2013","unstructured":"Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, et al. Gemcitabine-mediated tumor regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death Dis. 2013;4:e791.","journal-title":"Cell Death Dis"},{"key":"3062_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.117443","volume":"240","author":"M Ashrafizadeh","year":"2024","unstructured":"Ashrafizadeh M, Luo K, Zhang W, Reza Aref A, Zhang X. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: environmental factors, molecular profile and drug\/nanotherapeutic approaches. Environ Res. 2024;240:117443.","journal-title":"Environ Res"},{"key":"3062_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.pan.2016.12.013","volume":"17","author":"A Rajabpour","year":"2017","unstructured":"Rajabpour A, Rajaei F, Teimoori-Toolabi L. Molecular alterations contributing to pancreatic cancer chemoresistance. Pancreatology. 2017;17:310\u201320.","journal-title":"Pancreatology"},{"key":"3062_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"RJ Shaw","year":"2006","unstructured":"Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424\u201330.","journal-title":"Nature"},{"key":"3062_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/sj.bjc.6601037","volume":"89","author":"BN Fahy","year":"2003","unstructured":"Fahy BN, Schlieman M, Virudachalam S, Bold RJ. Akt inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer. 2003;89:391\u20137.","journal-title":"Br J Cancer"},{"key":"3062_CR39","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500\u20138.","journal-title":"Cancer Res"},{"key":"3062_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2019.05.037","volume":"459","author":"N Awasthi","year":"2019","unstructured":"Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, et al. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel\/gemcitabinecitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Lett. 2019;459:41\u20139.","journal-title":"Cancer Lett"},{"key":"3062_CR41","first-page":"5451","volume":"60","author":"SSW Ng","year":"2000","unstructured":"Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000;60:5451\u20135.","journal-title":"Cancer Res"},{"key":"3062_CR42","doi-asserted-by":"publisher","first-page":"15923","DOI":"10.1074\/jbc.M111.312413","volume":"287","author":"R Li","year":"2012","unstructured":"Li R, Chen DF, Zhou R, Jia SN, Yang JS, Clegg JS, et al. Involvement of polo-like kinase 1 (Plk1) in mitotic arrest by inhibition of mitogen-activated protein kinase-extracellular signal-regulated kinase-ribosomal S6 kinase 1 (MEK-ERK-RSK1) cascade. J Biol Chem. 2012;287:15923\u201334.","journal-title":"J Biol Chem"},{"key":"3062_CR43","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.1158\/0008-5472.CAN-14-1916","volume":"74","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, et al. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res. 2014;74:6635\u201347.","journal-title":"Cancer Res"},{"key":"3062_CR44","doi-asserted-by":"crossref","unstructured":"Ahn DH, Ridinger M, Cannon TL, Mendelsohn L, Starr JS, Hubbard JM, Kasi A, Barzi A, Samu\u00eblsz E, Karki A, Subramanian RA, Yemane D, Kim R, Wu CC, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. Onvansertib in combination with chemotherapy and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a single-arm, phase II trial. J Clin Oncol. 2024:JCO2401266.","DOI":"10.1200\/JCO-24-01266"},{"key":"3062_CR45","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-23-3053","volume":"30","author":"DH Ahn","year":"2024","unstructured":"Ahn DH, Barzi A, Ridinger M, Samu\u00eblsz E, Subramanian RA, Croucher PJP, et al. Onvansertib in combination with FOLFIRI and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a phase Ib clinical study. Clin Cancer Res. 2024;30:2039\u201347.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"3062_CR46","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","volume":"26","author":"AM Zeidan","year":"2020","unstructured":"Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA, et al. A phase Ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia. Clin Cancer Res. 2020;26(23):6132\u201340.","journal-title":"Clin Cancer Res"},{"key":"3062_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125708","volume":"26","author":"F Guffanti","year":"2025","unstructured":"Guffanti F, Mengoli I, Ricci F, Perotti L, Capellini E, Sala L, et al. Onvansertib-based second-line therapies in combination with gemcitabine and carboplatin in patient-derived platinum-resistant ovarian carcinomas. Int J Mol Sci. 2025;26:5708.","journal-title":"Int J Mol Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03062-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:03:19Z","timestamp":1762426999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03062-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3062"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03062-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7181022\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Committee of Henan Provincial People's Hospital, People's Hospital of Henan University (approval number: 2022-10-04-018). All human tumor tissues were obtained with oral consent obtained from all patients. The patients has been informed that the tissue specimen is used for a certain genetic testing and has no commercial or other purposes. This study adheres to the principles outlined in the Declaration of Helsinki. All animal experiments were conducted following the guidelines of the institutional animal committee of People's Hospital of Henan University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"508"}}